WSWilliam Shipman

William Shipman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Shipman has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic Spontaneous Urticaria in Skin of Color: Diagnostic Nuances and the Expanding Therapeutic Landscape

    by Milan V Carter, Chisom Nwosu, Sonal R Patel, William D Shipman

    Background: Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition characterized by recurrent urticaria that can significantly impact quality of life. CSU is diagnosed clinically, relying on patient history and skin examination. In skin of color (SOC) patients, hallmark findings, wheals and angioedema, may appear subtle or skin-colored, making physical findings difficult to appreciate. These nuances may delay diagnosis and reduce access to symptom-modifying therapies. Methods: A focused literature search was conducted on CSU, with a targeted review of articles discussing SOC, physical examination findings, diagnostic considerations, and available therapies. Results: Limited studies are currently available on CSU in SOC. Available studies note that CSU diagnosis may be more challenging in darker skin tones, but do not provide diagnostic frameworks. Current clinical guidelines do not stratify recommendations by skin tone. Conclusion: This review highlights potential challenges in recognizing CSU in patients with skin of color and provides practical diagnostic considerations, including assessment of lesion duration, palpation for wheals, recognition of angioedema, and use of patient-reported symptoms. Given the limited comparative evidence, further research is needed to characterize CSU presentation, diagnostic outcomes, and treatment responses across diverse skin tones.

  • Langerhans cell control of early-life dermal lymphatic development shapes adult immunity

    by Ji Hyun Sim, Richard Bell, Yurii Chinenov, Zhonghui Feng, Jinyeon Shin, Susan Chyou, William D. Shipman, Yue Xing, Shruti Naik, Niroshana Anandasabapathy, et al.

    The communication between skin and draining lymph nodes is crucial for immune responses to skin insults. Lymphatic vessels play key roles in this communication by transporting antigens from skin to lymph nodes, and mechanisms that compromise dermal lymphatic function can disrupt skin immunity. Here, we show that Langerhans cells (LCs), epidermis-derived antigen-presenting cells, promote dermal lymphatic expansion and phenotype acquisition during early life. This function was mediated by PlGF (placental growth factor) and VEGF-C (vascular endothelial growth factor C), and LCs selectively shaped the transcriptional profile of lymphatic endothelial cells. Compromise of this early-life LC-mediated lymphatic expansion reduced soluble antigen flow to draining lymph nodes and T cell responses in adulthood. Our data identify a tissue-based mechanism by which LCs regulate T cells remotely across time and space and raise the possibility that immune diseases in adulthood could reflect compromise of the LC-lymphatic axis in childhood.


  • An Update on Emerging Regenerative Medicine Applications: The Use of Extracellular Vesicles and Exosomes for the Management of Chronic Pain

    by William D. Shipman, Raquel Fonseca, Moises Dominguez, Sadiq Bhayani, Christopher Gilligan, Sudhir Diwan, David Rosenblum, Sait Ashina, Reda Tolba, Alaa Abd-Elsayed, et al.

    Purpose of Review Chronic pain affects nearly two billion people worldwide, surpassing heart disease, diabetes, and cancer in terms of economic costs. Lower back pain alone is the leading cause of years lived with disability worldwide. Despite limited treatment options, regenerative medicine, particularly extracellular vesicles (EVs) and exosomes, holds early promise for patients who have exhausted other treatment options. EVs, including exosomes, are nano-sized structures released by cells, facilitating cellular communication through bioactive molecule transfer, and offering potential regenerative properties to damaged tissues. Here, we review the potential of EVs and exosomes for the management of chronic pain. Recent Findings In osteoarthritis, various exosomes, such as those derived from synovial mesenchymal stem cells, human placental cells, dental pulp stem cells, and bone marrow-derived mesenchymal stem cells (MSCs), demonstrate the ability to reduce inflammation, promote tissue repair, and alleviate pain in animal models. In intervertebral disc disease, Wharton’s jelly MSC-derived EVs enhance cell viability and reduce inflammation. In addition, various forms of exosomes have been shown to reduce signs of inflammation in neurons and alleviate pain in neuropathic conditions in animal models. Summary Although clinical applications of EVs and exosomes are still in the early clinical stages, they offer immense potential in the future management of chronic pain conditions. Clinical trials are ongoing to explore their therapeutic potential further, and with more research the potential applicability of EVs and exosomes will be fully understood.


  • Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta‐analysis

    by William D. Shipman, Monica N. Williams, Kathleen C. Suozzi, Anna S. Eisenstein, Jeffrey S. Dover

    Objectives: Hidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by painful nodules, draining tunnels, and fibrotic scarring in intertriginous, hair‐bearing areas. The pathogenesis involves follicular occlusion and subsequent rupture, leading to uncontrolled inflammation. Treatment options for HS are limited and lack universal effectiveness. Laser hair removal (LHR) has been explored as a potential treatment; however, the efficacy and appropriate laser modalities remain unclear. This systematic review examined the efficacy and adverse effects of LHR in HS.Methods: A comprehensive literature search was conducted from inception to September 2023 in Ovid MEDLINE, Ovid Embase, and The Cochrane Library (Wiley) with predefined inclusion and exclusion criteria, and a meta‐analysis was conducted.Results: Ten studies were selected (n = 227 total patients) and included six randomized controlled trials, two nonrandomized experimental studies, and two case series. Various laser modalities, including long‐pulsed neodymium‐doped yttrium aluminum garnet (Nd:YAG) (n = 115), intense pulsed light (n = 18), Alexandrite (n = 54), intralesional 1064 nm diode (n = 20), and combined fractional CO2 and long‐pulsed Nd:YAG laser (n = 20), consistently demonstrated significant improvement in HS disease severity, irrespective of the disease scoring method used. Minimal adverse effects (primarily mild pain and erythema) were reported. A meta‐analysis of three studies utilizing long‐pulsed Nd:YAG laser demonstrated a standardized mean difference in disease severity of −1.68 (95% confidence interval: −2.99; −0.37), favoring treatment with LHR for HS.Conclusions: Hair follicles are key in HS pathogenesis and all included studies showed a significant improvement in HS disease severity after LHR regardless of the laser device used, likely related to hair follicle unit destruction. HS is a complex and heterogenous condition, and multiple disease scoring methods complicate outcome comparisons across studies. However, LHR, utilizing various techniques, is an effective treatment option for HS with minimal adverse effects.


  • Open Access

    201 Type I interferon modulates langerhans cell ADAM17 in lupus to contribute to photosensitivity

    by Thomas M Li, Keila R Veiga, Noa Schwartz, Jose Lora, Ali Jabbari, Yong Liu, William D Shipman, Marvin J Sandoval, Isabel F Sollohub, Mehdi Rashighi, et al.

    Background Photosensitivity is a common feature in systemic lupus erythematosus (SLE), is considered to be a major contributor to SLE skin disease, and can be associated with serious flares of systemic disease, but mechanistic understanding remains limited. Several lines of evidence including the finding of a type I interferon (IFN-I) signature in non-lesional skin, the potentiation of keratinocyte apoptosis by IFN-I, the importance of IFNAR in murine lupus model skin lesion development, and the improved skin scores in the clinical trials of anifrolumab (anti-IFNAR1) point to a pathogenic role for IFN-I in SLE skin disease. We recently showed that Langerhans cells (LCs) limit UVR-induced keratinocyte apoptosis and skin injury via ADAM17-mediated EGFR ligand activation and that reduced LC ADAM17 activity in two lupus models contributed to their photosensitivity. Non-lesional human SLE skin also showed evidence of a dysfunctional LC-keratinocyte axis; however, what causes LC dysfunction is not known. Here we test the hypothesis that IFN-I in the skin contributes to LC ADAM17 dysfunction and thus photosensitivity. Methods To assess IFN-I gene signature, microarray of non-lesional skin from human cutaneous LE and RNA sequencing of whole skin from lupus mouse models were performed. To quantify human and murine LC ADAM17 activity and expression, in vitro and ex vivo flow cytometric-based assays were conducted LCs. To assay photosensitivity, readouts of skin inflammation and cellular infiltrate were measured and characterized. Results We show that non-lesional skin from human cutaneous LE and photosensitive MRL/lpr and B6.Sle1yaa mice all share IFN-I signatures and that IFN-I is sufficient to reduce human and murine LC ADAM17 activity independently of surface ADAM17 levels. IFN-I induced LC ADAM17 activity defects were abrogated with tofaticinib, a JAK kinase inhibitor approved for rheumatoid arthritis and other rheumatologic diseases. We further show that anti-IFNAR1 treatment prior to UVR exposure in lupus models restores LC ADAM17 activity and limits photosensitivity. Conclusions Together, our results suggest a model whereby the elevated IFN-I in non-lesional skin contributes to photosensitivity at least in part by causing LC ADAM17 dysfunction. The corollary is that anti-IFNAR has beneficial effects at least in part by correcting LC ADAM17 dysfunction. Acknowledgements This work was supported by National Institutes of Health R01AI079178 (TTL), the Lupus Research Alliance (TTL), the St. Giles Foundation (TTL) and AΩA Carolyn L. Kuckein Student Research Fellowship (TML).

  • Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages

    by Carmelo Carmona-Rivera, Liam J. O’nEil, Eduardo Patino-Martinez, William D. Shipman, Chengsong Zhu, Quan-Zhen Li, Michelle L. Kerns, Leandra A. Barnes, Julie A. Caffrey, Sewon Kang, et al.


  • Clinical Trials and Skin of Color: The Example of Hidradenitis Suppurativa

    by Chidubem A.V. Okeke, Jessica D. Perry, Faith C. Simmonds, Azure B. Erskine, William D. Shipman, Janyla A. Seltzer, Marcus R. Andrews, Arjun D. Saini, Taylor A. Cole, Jamilah A. Perkins, et al.

    Despite the recent momentum of skin of color conversations in dermatology, adequate research on skin of color diseases is still lacking and African Americans/Blacks are often underrepresented in clinical trials. This underrepresentation is especially glaring in hidradenitis suppurativa (HS) clinical trials [1]. HS is a chronic inflammatory skin condition that commonly affects intertriginous areas and is characterized by painful nodules, draining sinus tracts, and hypertrophic scarring [2]. A recent systematic review focusing on racial populations reports the average prevalence rate of HS as highest in African Americans compared to both Whites and Hispanics/Latinos [3]. Additionally, a study evaluating 47,690 HS patients across the USA found that the disease affects 54.1% (25,780/47,690) Whites compared to 32.6% (15,540/47,690) African Americans; however, when standardized to the US population, the adjusted prevalence of HS was shown to disproportionately affect African American patients with a three-fold increase compared to Whites [4]. Taking into account the wide distribution of populations affected, African Americans are minimally included in HS clinical trials [1]. Of 15 phase II and III HS trials published over the last 12 years (2007–2019), 68% of the participants were Caucasian while only 14.0% were of African descent [1]. This disparity hinders our complete understanding of the therapeutic effects and responses in African Americans, which may lead to the development and use of HS treatments that are neither reflective nor fully applicable to diverse patient populations. The lack of racial and ethnic diversity in HS clinical trials has been highlighted in the literature [1], but barriers and possible explanations are still unclear. Herein we explore the lack of African American representation in these studies by examining the clinical trial locations within the USA and by discussing potential barriers to African American inclusion.


  • Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa

    by Janyla A. Seltzer, Chidubem A.V. Okeke, Jessica D. Perry, William D. Shipman, Ginette A. Okoye, Angel S. Byrd


  • Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas

    by Chidubem A. V. Okeke, William D. Shipman, Jessica D. Perry, Michelle L. Kerns, Ginette A. Okoye, Angel S. Byrd

    (2020). Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas. Journal of Dermatological Treatment. Ahead of Print.


  • Lymph node stromal CCL2 limits antibody responses

    by Dragos C. Dasoveanu, Hyeung Ju Park, Catherine L. Ly, William D. Shipman, Susan Chyou, Varsha Kumar, David Tarlinton, Burkhard Ludewig, Babak J. Mehrara, Theresa T. Lu

    Nonhematopoietic stromal cells in lymph nodes such as fibroblastic reticular cells (FRCs) can support the survival of plasmablasts and plasma cells [together, antibody-forming cells (AFCs)]. However, a regulatory function for the stromal compartment in AFC accumulation has not been appreciated. Here, we show that chemokine ligand 2 (CCL2)–expressing stromal cells limit AFC survival. FRCs express high levels of CCL2 in vessel-rich areas of the T cell zone and the medulla, where AFCs are located. FRC CCL2 is up-regulated during AFC accumulation, and we use lymph node transplantation to show that CCL2 deficiency in BP3+ FRCs and lymphatic endothelial cells increases AFC survival without affecting B or germinal center cell numbers. Monocytes are key expressers of the CCL2 receptor CCR2, as monocyte depletion and transfer late in AFC responses increases and decreases AFC accumulation, respectively. Monocytes express reactive oxygen species (ROS) in an NADPH oxidase 2 (NOX2)–dependent manner, and NOX2-deficient monocytes fail to reduce AFC numbers. Stromal CCL2 modulates both monocyte accumulation and ROS production, and is regulated, in part, by manipulations that modulate vascular permeability. Together, our results reveal that the lymph node stromal compartment, by influencing monocyte accumulation and functional phenotype, has a regulatory role in AFC survival. Our results further suggest a role for inflammation-induced vascular activity in tuning the lymph node microenvironment. The understanding of stromal-mediated AFC regulation in vessel-rich environments could potentially be harnessed to control antibody-mediated autoimmunity.